FindTrial
Sign In

buparlisib (BKM120)

DRUG2 trials

Sponsors

Novartis Pharmaceuticals, Memorial Sloan Kettering Cancer Center

Conditions

LymphomaPI3K Pathway InhibitionPre-menopausal Breast CancerPrimary Central Nervous System LymphomaRecurrent/Refractory Secondary Central Nervous System Lymphoma

Phase 1

A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer
CompletedNCT02058381
Novartis PharmaceuticalsPI3K Pathway Inhibition, Pre-menopausal Breast Cancer
Start: 2014-05-06End: 2018-06-19Updated: 2020-03-09

Phase 2

Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)
CompletedNCT02301364
Memorial Sloan Kettering Cancer CenterLymphoma, Primary Central Nervous System Lymphoma, Recurrent/Refractory Secondary Central Nervous System Lymphoma
Start: 2014-11-20End: 2016-10-11Updated: 2017-10-19

Related Papers

Preclinical and clinical evaluation of Buparlisib (BKM120) in recurrent/refractory Central Nervous System Lymphoma
Leukemia & lymphoma/Leukemia and lymphoma2023-06-158 citations
Abstract P4-13-27: A phase Ib dose de-escalation study of combined tamoxifen and goserelin acetate with alpelisib (BYL719) or buparlisib (BKM120) in premenopausal patients with HR+/HER2– locally advanced or metastatic breast cancer
Cancer Research2016-02-154 citations